STOCK TITAN
  1. Home
  2. News
  3. ACIU

AC Immune SA - ACIU STOCK NEWS

Welcome to our dedicated news page for AC Immune SA (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AC Immune SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AC Immune SA's position in the market.

News
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
Rhea-AI Summary
AC Immune reports positive financial results and progress in clinical trials for neurodegenerative diseases. The company's active immunotherapy programs in Alzheimer's and Parkinson's diseases are advancing well, with key milestones expected in 2024. Financially, AC Immune has a strong cash position and recorded increased contract revenues in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
earnings
-
News
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
Rhea-AI Summary
AC Immune SA (NASDAQ: ACIU) announces upcoming presentations at AD/PD™ 2024. Andrea Pfeifer, Ph.D., CEO, to lead AC Immune-sponsored symposium on alpha-synuclein pathologies. The presentations will highlight the precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) in Lisbon, Portugal from March 5-9, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences
-
News
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
Rhea-AI Summary
AC Immune SA (NASDAQ: ACIU) announced the termination of collaboration agreements with Genentech and Roche, regaining global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab. The company will carefully review available data sets before deciding on potential further development and other opportunities. AC Immune is focused on progressing its three active immunotherapies from its precision medicine pipeline, with ongoing Phase 2 clinical trials, potentially revolutionizing how neurodegenerative diseases are addressed. The company is well financed into 2026 and able to advance multiple high-value development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
none
News
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
Rhea-AI Summary
AC Immune (NASDAQ: ACIU) announces positive progress in its active immunotherapy programs, with three Phase 2 trials progressing to key clinical milestones in 2024. The company's financial position was reinforced with a successful USD50 million equity offering and a CHF15 million milestone payment. ACI-24.060, ACI-7104.056, and ACI-35.030 are all progressing well, with milestones expected in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
clinical trial
-
News
AC Immune Announces Pricing of Underwritten Offering of Common Shares
Rhea-AI Summary
AC Immune SA (ACIU) has priced an underwritten offering of 14.3 million common shares at USD 3.50 per share, expecting gross proceeds of approximately USD 50.1 million. The equity offering was led by BVF Partners L.P. and will be used to invest in research, clinical development, technology platforms, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
offering
-
News
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
Rhea-AI Summary
AC Immune SA (NASDAQ: ACIU) announces the advancement of ACI-35.030, an anti-pTau active immunotherapy, into a Phase 2b trial for preclinical Alzheimer's disease. The study, ReTain, aims to evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants. The trial is designed to potentially prevent or reduce cognitive decline, addressing the need of over 315 million people globally with preclinical AD. AC Immune will receive approximately CHF 40 million in total milestone payments under terms of the licensing agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
clinical trial
News
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
Rhea-AI Summary
AC Immune (NASDAQ: ACIU) appoints Dr. Madiha Derouazi as CSO and Christopher Roberts as CFO. Dr. Derouazi, an accomplished immunologist, was previously CEO of Speransa Therapeutics and founded AMAL Therapeutics, while Christopher Roberts has extensive experience in finance. The retiring CSO, Dr. Marie Kosco-Vilbois, will remain as a consultant to ensure a smooth transition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
management
-
News
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
Rhea-AI Summary
AC Immune SA (NASDAQ: ACIU) will participate in the Jefferies 2023 London Healthcare Conference, including a fireside chat and one-on-one investor meetings. The fireside chat is scheduled for November 16, 2023, at 6:30 AM (ET) / 11:30 AM (GMT), with a webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
conferences
-
News
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Rhea-AI Summary
AC Immune reported its financial results for Q3 2023 and provided a corporate update. The company is on track to report safety and immunogenicity data from the AD cohort of its ABATE trial by year-end. Results from amyloid plaque reduction analysis after 6 months of treatment are expected in H1 2024. The company also highlighted progress in its pipeline, including the initiation of a Phase 2 trial for ACI-7104.056 in Parkinson's disease. AC Immune's cash position is CHF 79.9 million, which will finance the company into Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
earnings
News
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
Rhea-AI Summary
AC Immune will host a KOL webinar on amyloid plaque PET imaging in Alzheimer's Disease on November 9, 2023. Prof. Victor Villemagne will discuss the methodology and clinical implications of plaque lowering. AC Immune will also highlight its anti-Abeta active immunotherapy candidate, ACI-24.060, currently being evaluated in the Phase 1b/2 ABATE study. Initial amyloid-PET imaging analyses are expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
conferences
Stock ACIU logo
AC Immune SA

Nasdaq:ACIU

ACIU Rankings

#3628 Ranked by Market Cap
#2037 Ranked by Stock Gains
N/A Ranked by Dividends

ACIU Stock Data

242.30M
39.64M
41.87%
30.23%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Lausanne

About ACIU

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor